Losa Carlos Alberto Allepuz, Fernando Angel Borque, Lázaro Vicente Andrés, Berlanga Francesc Filipo, Frago Patricia Serrano, López Marta Allúe, Sanz María Jesús Gil, Martínez Pedro Gil, Sanz Luis Angel Rioja
Servicio de Urología, Hospital Universitario Miguel Servet, Pso. Isabel la Católica, 1 y 3, 50009 Zaragoza, España.
Arch Esp Urol. 2006 Dec;59(10):977-88.
To evaluate if radical prostatectomy may positively influence cancer-specific survival (CSS), hormone-resistance-free time, metastasis-free time, and quality of life(QoL) of patients with prostate adenocarcinoma and seminal vesicle invasion, and also to update our thoughts about seminal vesicle biopsy.
114 patients were included. Forty-six cases were diagnosed of seminal vesicle invasion after radical prostatectomy; 68 cases were diagnosed of seminal vesicle invasion after biopsy, not undergoing then surgery. Cancer specific survival, time to hormone resistance from the start of hormonal treatment, metastasis free time and QoL, measured as need for hospital care, were compared between groups. Median follow-up time was 52.6 mos.
There were not statistically significant differences between groups in CSS, time to hormone resistance, metastasis free time and QoL. Three and five-year cancer specific survival were 100% and 80.77% for the radical prostatectomy group and 74.4% and 56.2% for the biopsy group. Primary grade and Gleason Score were independent predictors for CSS in the Cox regression test; clinical stage was independent predictor for time to hormone resistance.
Radical prostatectomy as monotherapy does not show a statistically significant influence on followup time, CSS, time to hormone resistance, metastasis free time or QoL in patients with prostate cancer and seminal vesicle invasion associated with other bad prognostic factors (unfavourable Gleason and PSA). The value of seminal vesicle biopsy remains for the study of new multimodal treatments, such as chemotherapy + surgery, and it is to be defined in the planning of radio and cryosurgery.
评估根治性前列腺切除术是否会对伴有精囊侵犯的前列腺腺癌患者的癌症特异性生存(CSS)、无激素抵抗时间、无转移时间及生活质量(QoL)产生积极影响,同时更新我们对精囊活检的认识。
纳入114例患者。46例在根治性前列腺切除术后被诊断为精囊侵犯;68例在活检后被诊断为精囊侵犯,之后未接受手术。比较两组之间的癌症特异性生存、从开始激素治疗至出现激素抵抗的时间、无转移时间以及以住院护理需求衡量的生活质量。中位随访时间为52.6个月。
两组在CSS、激素抵抗时间、无转移时间和生活质量方面无统计学显著差异。根治性前列腺切除术组的3年和5年癌症特异性生存率分别为100%和80.77%,活检组分别为74.4%和56.2%。在Cox回归检验中,原发分级和Gleason评分是CSS的独立预测因素;临床分期是激素抵抗时间的独立预测因素。
对于伴有精囊侵犯且存在其他不良预后因素(不利的Gleason评分和PSA)的前列腺癌患者,单纯根治性前列腺切除术对随访时间、CSS、激素抵抗时间、无转移时间或生活质量未显示出统计学显著影响。精囊活检的价值仍在于新的多模式治疗研究,如化疗+手术,并且在放疗和冷冻手术规划中有待明确。